Piermont Capital Management’s Amphastar Pharmaceuticals AMPH Stock Holding History

Piermont Capital Management’s Portfolio AMPH Stock Details AMPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-10,870	Closed	-$204K	–	237
2018 Q1	$204K	Sell	10,870 -1,860	-15%	-$35K	0.07%	232
2017 Q4	$245K	Sell	12,730 -760	-6%	-$14.2K	0.08%	225
2017 Q3	$241K	Sell	13,490 -14,033	-51%	-$231K	0.08%	232
2017 Q2	$492K	Sell	27,523 -5,160	-16%	-$81.8K	0.14%	228
2017 Q1	$474K	Buy	32,683 +6,530	+25%	+$103K	0.11%	235
2016 Q4	$482K	Sell	26,153 -510	-2%	-$9.92K	0.11%	228
2016 Q3	$506K	Buy	+26,663	New	+$484K	0.12%	235

Other funds holding AMPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CAM

Cortina Asset Management Milwaukee, Wisconsin $1.62B AUM 15.44% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Piermont Capital Management's AMPH Position: Q2 2018 in Review

Piermont Capital Management sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2018, closing a stake of 10,870 shares — an estimated $204K sold.

Piermont Capital Management first reported a position in AMPH in Q3 2016 and held it in 7 quarters. The position peaked at $506K in Q3 2016. 114 funds tracked by Wall St. Rank hold AMPH as of Q2 2018.

Piermont Capital Management reported no remaining Amphastar Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Piermont Capital Management sold 10,870 Amphastar Pharmaceuticals shares in Q2 2018, an estimated $204K.
Piermont Capital Management first reported a position in Amphastar Pharmaceuticals in Q3 2016 and held it in 7 quarters.
Piermont Capital Management's Amphastar Pharmaceuticals position peaked at $506K in Q3 2016.
114 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2018.

Based on Piermont Capital Management's 13F filing for Q2 2018, filed 10 Aug 2018.